国际肿瘤学杂志››2013,Vol. 40››Issue (6): 472-475.

• 综述 •上一篇下一篇

PCI-32765在治疗B细胞恶性肿瘤中的应用

屈福莲, 夏冰, 张翼鷟

  1. 300060天津医科大学附属肿瘤医院肿瘤防治重点实验室
  • 出版日期:2013-06-08发布日期:2013-05-24
  • 通讯作者:张翼鷟,E-mail:aprilzyz@yahoo.com E-mail:aprilzyz@yahoo.com

Clinical application of PCI-32765 for the treatment of B cell malignancies

QU Fu-Lian, XIA Bing, ZHANG Yi-Zhuo

  1. Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

  • Online:2013-06-08Published:2013-05-24
  • Contact:ZHANG Yi-zhuo E-mail:aprilzyz@yahoo.com

摘要:PCI-32765是一种口服的Bruton酪氨酸激酶(BTK)抑制剂,可通过选择性、不可逆地抑制BTK,阻断B细胞受体信号通路,抑制B细胞的生存、活化、增殖和迁移。PCI-32765不仅能直接作用于恶性肿瘤B细胞,还能防止肿瘤细胞产生耐药性。因此,PCI-32765在B细胞恶性肿瘤的治疗中具有广阔的应用前景。

关键词:淋巴瘤,药物疗法,信号转导

Abstract:PCI-32765, an oral selective and irreversible inhibitor of Bruton tyrosine kinase (BTK), inhibits survival, activation, proliferation and migration of malignant B cells by blocking B cell receptor signaling pathway.PCI-32765 not only acts on malignant B cell, but also prevents resistance to chemical drugs. Therefore, PCI-32765 has broad prospects in the treatment of B cell malignancies.

Key words:Lymphoma,Drug therapy,Signal transducing